{
  "source": "PA-Notification-Dupixent.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1207-17\nProgram Prior Authorization/Notification\nMedications Dupixent® (dupilumab)\nP&T Approval Date 1/2017, 5/2017, 5/2018, 12/2018, 4/2019, 8/2019, 6/2020, 6/2021,\n12/2021, 7/2022, 11/2022, 3/2023, 7/2023, 3/2024, 11/2024, 3/2025,\n6/2025\nEffective Date 9/1/2025\n1. Background:\nDupixent® (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for treatment of\npatients aged 6 months and older with moderate to severe atopic dermatitis whose disease is not\nadequately controlled with topical prescription therapies or when those therapies are not\nadvisable. Dupixent can be used with or without topical corticosteroids. Dupixent is also\nindicated as an add-on maintenance treatment in patients with moderate-to-severe asthma aged\n6 years and older with an eosinophilic phenotype or with oral corticosteroid dependent asthma,\nas an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with\ninadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP), for the\ntreatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with\neosinophilic esophagitis (EoE), for adult patients with prurigo nodularis (PN), as add-on\nmaintenance treatment of adult patients with inadequately controlled chronic obstructive\npulmonary disease (COPD) and an eosinophilic phenotype, and pediatric patients aged 12 years\nand older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1\nantihistamine treatment..\nLimitation of Use:\nDupixent is not for the relief of acute bronchospasm or status asthmaticus.\n2. Coverage Criteriaa:\nA. Atopic Dermatitis\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe chronic atopic dermatitis\n-AND-\n(2) History of failure, contraindication, or intolerance to topical therapies\n-AND-\n(3) Patient is not receiving Dupixent in c",
    "eria:\n(1) Diagnosis of moderate to severe chronic atopic dermatitis\n-AND-\n(2) History of failure, contraindication, or intolerance to topical therapies\n-AND-\n(3) Patient is not receiving Dupixent in combination with either of the following for\ntreatment of the same indication:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy\n-AND-\n(2) Patient is not receiving Dupixent in combination with either of the following for\ntreatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\nAuthorization will be issued for 12 months.\nB. Asthma\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of moderate-to-severe asthma\n-AND-\n(2) Dupixent will be used in combination with maintenance therapy [e.g.,\nAdvair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone\nfuroate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone\nfuroate/umeclidinium/vilanterol)].\n-AND-\n(3) One of the following:\n(a) Patient has an eosinophilic phenotype\n-OR-\n(b) Patient is currently dependent on oral corticosteroids for the treatment of asthma\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(4) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (resilizumab),\nFasenra (benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic",
    "treatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (resilizumab),\nFasenra (benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy\n-AND-\n(2) Dupixent is being used in combination with maintenance therapy [e.g.,\nAdvair/AirDuo (fluticasone/salmeterol), Breo Ellipta (fluticasone\nfuroate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone\nfuroate/umeclidinium/vilanterol)].\n-AND-\n(3) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (resilizumab),\nFasenra (benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\nAuthorization will be issued for 12 months.\nC. Chronic Rhinosinusitis with Nasal Polyposis\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP)\n-AND-\n(2) Patient will receive Dupixent as add-on maintenance therapy in combination with\nintranasal corticosteroids\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n3\n(3) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab),\nNucala (mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteri",
    " stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy\n-AND-\n(2) Patient will continue to receive Dupixent as add-on maintenance therapy in\ncombination with intranasal corticosteroids\n-AND-\n(3) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab),\nNucala (mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\nAuthorization will be issued for 12 months.\nD. Eosinophilic Esophagitis\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of eosinophilic esophagitis\n-AND-\n(2) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab),\nNucala (mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n© 2025 UnitedHealthcare Services, Inc.\n4\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy\n-AND-\n(2) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra (benralizumab),\nNucala (mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\nAuthorization will be issued for 12 months.\nE. Prurigo Nodularis\n1. Ini",
    "b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\nAuthorization will be issued for 12 months.\nE. Prurigo Nodularis\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of prurigo nodularis\n-AND-\n(2) Patient is not receiving Dupixent in combination with either of the following for\ntreatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Nemluvio\n(nemolizumab-ilto)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n5\n(2) Patient is not receiving Dupixent in combination with either of the following for\ntreatment of the same indication:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Nemluvio\n(nemolizumab-ilto)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\nAuthorization will be issued for 12 months.\nF. Chronic Obstructive Pulmonary Disorder (COPD)\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of COPD\n-AND-\n(2) Patient has an eosinophilic phenotype\n-AND-\n(3) Dupixent will be used in combination with maintenance therapy [e.g.,\nAdvair/AirDuo (fluticasone/salmeterol), Bevespi Aerosphere\n(glycopyrrolate/formoterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort\n(budesonide/formoterol), Trelegy Ellipta (fluticasone\nfuroate/umeclidinium/vilanterol)].\n-AND-\n(4) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy",
    "fluticasone\nfuroate/umeclidinium/vilanterol)].\n-AND-\n(4) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (resilizumab),\nFasenra (benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n6\n(2) Dupixent is being used in combination with maintenance therapy [e.g.,\nAdvair/AirDuo (fluticasone/salmeterol), Bevespi Aerosphere\n(glycopyrrolate/formoterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort\n(budesonide/formoterol), Trelegy Ellipta (fluticasone\nfuroate/umeclidinium/vilanterol)]\n-AND-\n(3) Patient is not receiving Dupixent in combination with any of the following for\ntreatment of the same indication:\n(a) Anti-interleukin-5 therapy [e.g., Nucala (mepolizumab), Cinqair (resilizumab),\nFasenra (benralizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]\nAuthorization will be issued for 12 months.\nG. Chronic Spontaneous Urticaria\n1. Initial Authorization\na. Dupixent will be approved based on all of the following criteria:\n(1) Diagnosis of chronic spontaneous urticaria\n-AND-\n(2) Patient remains symptomatic despite H1 antihistamine treatment [e.g., cetirizine\n(Zyrtec), fexofenadine (Allegra), loratadine (Claritin)]\n-AND-\n(3) Patient is not receiving Dupixent in combination with Xolair (omalizumab) for\ntreatment of the same indication\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Dupixent",
    "ication\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Dupixent will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Dupixent therapy\n-AND-\n(2) Patient is not receiving Dupixent in combination with Xolair (omalizumab) for\ntreatment of the same indication\n© 2025 UnitedHealthcare Services, Inc.\n7\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limitations may be in place.\n• Medical Necessity may be in place.\n4. References:\n1. Dupixent® [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc. April 2025.\nProgram Prior Authorization/Notification - Dupixent (dupilumab)\nChange Control\n1/2017 New program.\n5/2017 Updated background and references. Dupixent approved on 3/28/2017.\n5/2018 Annual review. No changes to criteria.\n12/2018 Updated background and formatting and added criteria for new indication\nfor moderate-to severe asthma.\n4/2019 Updated background and criteria for updated indication of adolescent\natopic dermatitis.\n8/2019 Updated background and criteria for updated indication of CRSwNP.\n6/2020 Updated background and criteria to include new indication for moderate-\nto-severe atopic dermatitis in children aged 6 to 11 years. Updated initial\nauthorization to 12 months.\n6/2021 Updated background and examples with no change to coverage criteria.\nUpdated references.\n12/2021 Updated background and criteria to include expanded indication of\nmoderate to severe eosinop",
    "hs.\n6/2021 Updated background and examples with no change to coverage criteria.\nUpdated references.\n12/2021 Updated background and criteria to include expanded indication of\nmoderate to severe eosinophilic or oral corticosteroid dependent asthma to\npatients aged 6 years and older. Updated references.\n7/2022 Updated criteria to include new indication for eosinophilic esophagitis.\nUpdated not used in combination examples for all indications. Updated\natopic dermatitis criteria and background to reflect patients older than 6\nmonths. Added state mandate footnote. Updated background and\nreference.\n11/2022 Updated criteria to include new indication for prurigo nodularis. Updated\nreference.\n3/2023 Updated not used in combination criteria for atopic dermatitis and prurigo\nnodularis.\n7/2023 Within the Asthma section, updated examples of maintenance therapy.\nThroughout program, removed age requirements.\n3/2024 Removed weight requirement from Eosinophilic Esophagitis criteria.\n© 2025 UnitedHealthcare Services, Inc.\n8\nUpdated background and reference.\n11/2024 Added coverage criteria section for chronic obstructive pulmonary\ndisorder. Updated background and reference.\n3/2025 Increased authorizations for eosinophilic esophagitis to 12 months.\n6/2025 Added criteria to include new indication for chronic spontaneous urticaria.\nUpdated coverage criteria for concomitant use. Updated approval duration\nfor prurigo nodularis. Added Nemluvio to the list of examples of biologic\nimmunomodulators for prurigo nodularis. Updated background and\nreference.\n© 2025 UnitedHealthcare Services, Inc.\n9"
  ]
}